Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

Genmab ( ($GMAB) ) has issued an update. On August 12, 2025, Genmab A/S announced a capital increase of 4,563 shares following the exercise of ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

European shares hit a near two-week high on Wednesday, underpinned by gains in heavyweight healthcare and technology stocks, ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...

The study involves several experimental treatment arms, each testing different combinations of epcoritamab with oral and intravenous drugs like lenalidomide, ibrutinib, and polatuzumab vedotin, ...